Reducing the dose of Kaftrio (elexacaftor, tezacaftor, and ivacaftor) should be considered for cystic fibrosis (CF) patients who…
Articles by Andrea Lobo, PhD
The Cystic Fibrosis Foundation is funding up to $3.9 million to TB Alliance to conduct preclinical studies of…
First Wave BioPharma has completed patient screening for the Phase 2 SPAN clinical trial of a new formulation of…
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor, tezacaftor, and ivacaftor) to…
SPRIM Global Investments (SGI) has committed $4.5 million to initiate Spexis’ Phase 3 COPILOT clinical trial to test the…
The Cystic Fibrosis Foundation (CFF) is investing up to $15.5 million in Anagram Therapeutics to conduct early-stage trials…
Pulmonary exacerbations in children with cystic fibrosis (CF) caused by multiple bacteria (polymicrobial) are generally treated with antibiotics that…
An exclusive telehealth care model used during the COVID-19 pandemic was associated with a decrease in pulmonary function in Australian…
Neither exercise nor nutritional interventions were found to affect the microbial population — typically an underlying cause of lung function…
A Phase 2 clinical trial of an optimized formulation of adrulipase, a yeast-derived enzyme to treat exocrine pancreatic insufficiency (EPI)…